Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05105048 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05105048 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 9 participants.
The verdict
NCT05105048, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety, reactogenicity, and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive Japanese adults 18 to 40 years of age in the United States.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1647
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-11-08 |
| Est. Completion | 2023-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05105048
The ClinicalTrials.gov registry entry for NCT05105048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05105048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05105048 about?
NCT05105048 is a clinical study titled "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647". The main objective of this study is to evaluate the safety, reactogenicity, and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive Japanese adults 18 to 40 years of age in the United States...
What is the current status of trial NCT05105048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-11-08. Estimated completion is 2023-08-10.
What interventions are being tested in trial NCT05105048?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1647 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05105048?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.